bladder cancer

Showing 13 posts of 28 posts found.


Roche’s Tecentriq scores approvals in metastatic lung and bladder cancer

September 27, 2017
Research and Development, Sales and Marketing Cancer, EMA, EU, European Commission, Roche, bladder cancer, immunotherapy, lung cancer, pharma, tecentriq

It’s good news for Roche as the company’s immunotherapy drug Tecentriq secures approval from the European Commission to be used …

Lilly’s Cyramza combo boasts strong results in bladder cancer

September 11, 2017
Research and Development, Sales and Marketing Eli Lilly, bladder cancer, cyramza, immunotherapy, pharma

Eli Lilly has announced new Phase 3 data at the European Society for Medical Oncology 2017 Congress which further add …

BMS’ Opdivo scores eighth approval in Europe for bladder cancer

June 5, 2017
Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, Europe, European Commission, bladder cancer, immunotherapy

Bristol-Myers Squibb has announced that its flagship immunotherapy treatment Opdivo (nivolumab) has secured its eighth approval in Europe as the …


Potential blockbuster AZ immunotherapy secures FDA approval

May 2, 2017
Manufacturing and Production, Sales and Marketing AstraZeneca, bladder cancer, darzalex

The FDA has granted accelerated approval to AstraZeneca’s (AZ) immunotherapy therapy Imfinzi (durvalumab) for the treatment of locally advanced or …

FDA clears Opdivo to treat most common form of bladder cancer

February 6, 2017
Sales and Marketing BMS, Bristol-Myers Squibb, MSD, bladder cancer, immunotherapy, keytruda, opdivo

Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. …


Roche’s Tecentriq scores another bladder cancer Priority Review

January 9, 2017
Sales and Marketing Roche, bladder cancer, tecentriq

Roche has announced that its immunotherapy drug Tecenetriq (atezolizumab) has been awarded Priority Review by the FDA for the treatment …

Bristol-Myers Squibb’s Opdivo gets US FDA breakthrough therapy designation for advanced bladder cancer

June 28, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, bladder cancer, opdivo, regulation

Bristol-Myers Squibb (NYSE:BMY) said the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to its immunotherapy Opdivo for the …


FDA grants accelerated approval for Roche’s bladder cancer immunotherapy Tecentriq

May 19, 2016
Research and Development, Sales and Marketing FDA, Roche, atezolizumab, bladder cancer, immunotherapy, tecentriq

Roche (SIX: RO) has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Tecentriq (atezolizumab) …

Genentech cancer immunotherapy gets Priority FDA Review in bladder cancer

March 15, 2016
Manufacturing and Production, Research and Development FDA, Genentech, Roche, atezolizumab, bladder cancer, priority review

The US FDA has granted Roche subsidiary Genentech a Priority Review for atezolizumab in treating advanced bladder cancer, whose disease …


AZ’s durvalumab awarded breakthrough status in bladder cancer

February 18, 2016
Research and Development AstraZeneca, FDA, bladder cancer

AstraZeneca, and its biologics/R&D arm MedImmune, have won FDA Breakthrough Therapy status for their bladder cancer drug durvalumab (MEDI4736), which …

Roche building

Roche presents new data for advanced bladder cancer immunotherapy

January 8, 2016
Medical Communications, Research and Development Roche, atezolizumab, bladder cancer

Roche has announced updated results from a pivotal Phase II study, showing its investigational cancer immunotherapy atezolizumab extended median progression …

Actos image

Takeda and Lilly get Actos trial reprieve

October 29, 2014
Sales and Marketing Actos, Takeda, bladder cancer, diabetes, lilly

A judge has dramatically reduced the $9 billion damages bill Takeda and Lilly were set to pay over safety allegations …


Roche gets oncology boost with cancer vaccine

May 16, 2014
Research and Development, Sales and Marketing ASCO, Roche, bladder cancer, oncology

Roche’s most advanced experimental cancer immunotherapy has had impressive results in a small Phase I trial, reducing tumour size in …

Latest content